Abdullah Yahya Abdullah Alzahrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdullah Yahya Abdullah Alzahrani has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Arulraj Ramalingam
Department of Chemistry, Sri Manakula Vinayagar Engineering College, Madagadipet, Puducherry 605107, India
1 shared publication - Israa Jameel Hakeem
Department of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia
1 shared publication Jan Mohammad Mir
Multidisciplinary Chemistry Laboratory, Department of Chemistry, Islamic University of Science and Technology, Kashmir, J&K-192122, India
1 shared publicationKarpagam Ezhilarasan
Department of Chemistry, Annamalai University, Annamalai Nagar, Chidambaram 608 002, Tamil Nadu, India
1 shared publication- Manzoor Ahmad Rather
Department of Chemistry, IUST-Awantipora, India
1 shared publication Munirah Muhammad Al-Rooqi
Department of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia
1 shared publication
Latest Publications
- 6 November 2026
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Chimie
- Vol. 29 (G1) , 669-707
Plant-based natural products against multidrug-resistant cancers: mechanisms of apoptosis induction and cell cycle modulation with a focus on breast cancer
Breast cancer (BC) is a frequently diagnosed cancer in women worldwide and imposes a significant burden on healthcare systems. Although chemotherapy remains a primary treatment modality, its efficacy is often compromised by multidrug resistance (MDR), leading to poor clinical outcomes and treatment failure. Multidrug resistance in BC arises through multiple mechanisms, including decreased apoptotic activity, overexpression of ATP-binding cassette (ABC) transporters, alterations in the tumor microenvironment, enhanced DNA repair capacity, and epithelial–mesenchymal transition. Conventional chemotherapeutic agents such as doxorubicin and paclitaxel are effective against BC cells; however, their clinical utility is limited by MDR, severe side effects including cardiotoxicity and neuropathy, and reduced efficacy in resistant tumors. To address these challenges, natural products interfere with resistance mechanisms through diverse pathways, inhibiting efflux pumps such as P-glycoprotein, restoring apoptosis, and modulating signal transduction pathways, including PI3K/Akt and NF- κ B. Furthermore, they induce autophagy, inhibit unregulated cell growth, and modify the tumor microenvironment to enhance therapeutic response. Compounds such as curcumin, silybin, apigenin, berberine, matrine, and β -elemene have been shown to improve the effectiveness of chemotherapy, whether used as monotherapies or in combination with conventional drugs, while exhibiting minimal side effects compared to synthetic medicines. In conclusion, secondary metabolites derived from plants possess significant potential to overcome MDR in breast cancer. Their ability to attack resistance-related mechanisms through multiple pathways not only enhances the effectiveness of current therapy but also offers a promising source of safer and more effective anticancer agents.
- 6 November 2026
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Chimie
- Vol. 29 (G1) , 669-707
Plant-based natural products against multidrug-resistant cancers: mechanisms of apoptosis induction and cell cycle modulation with a focus on breast cancer
Breast cancer (BC) is a frequently diagnosed cancer in women worldwide and imposes a significant burden on healthcare systems. Although chemotherapy remains a primary treatment modality, its efficacy is often compromised by multidrug resistance (MDR), leading to poor clinical outcomes and treatment failure. Multidrug resistance in BC arises through multiple mechanisms, including decreased apoptotic activity, overexpression of ATP-binding cassette (ABC) transporters, alterations in the tumor microenvironment, enhanced DNA repair capacity, and epithelial–mesenchymal transition. Conventional chemotherapeutic agents such as doxorubicin and paclitaxel are effective against BC cells; however, their clinical utility is limited by MDR, severe side effects including cardiotoxicity and neuropathy, and reduced efficacy in resistant tumors. To address these challenges, natural products interfere with resistance mechanisms through diverse pathways, inhibiting efflux pumps such as P-glycoprotein, restoring apoptosis, and modulating signal transduction pathways, including PI3K/Akt and NF- κ B. Furthermore, they induce autophagy, inhibit unregulated cell growth, and modify the tumor microenvironment to enhance therapeutic response. Compounds such as curcumin, silybin, apigenin, berberine, matrine, and β -elemene have been shown to improve the effectiveness of chemotherapy, whether used as monotherapies or in combination with conventional drugs, while exhibiting minimal side effects compared to synthetic medicines. In conclusion, secondary metabolites derived from plants possess significant potential to overcome MDR in breast cancer. Their ability to attack resistance-related mechanisms through multiple pathways not only enhances the effectiveness of current therapy but also offers a promising source of safer and more effective anticancer agents.
- 17 March 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 26 (02) , 1-23
Oxazinyl-Thiazolidinone Hybrids: Integrated Synthesis, Anticancer Activity, Molecular Docking and In-silico Pharmacokinetic Evaluation
A series of 3-(6-(furan-2-yl)-4-(4-nitrophenyl)-6H-1,3-oxazin-2-yl)-2-phenylthiazolidin-4-one derivatives (15–19) were synthesized via a silica-supported method and comprehensively characterized using FT-IR, 1 H and [ ]C NMR and mass spectrometry. The anticancer potential of these thiazolidinone–oxazine hybrids was evaluated against the MCF-7 breast cancer cell line using the MTT assay. All compounds displayed moderate cytotoxic activity, with IC[ ] values ranging from 51.20 to 87.10 [ ]M. Among them, the nitro-substituted compound 15 exhibited the highest cytotoxic potency (IC[ ] 51.20 [ ]M), which may be attributed to the electron-withdrawing effect of the nitro group. To rationalize the experimental findings, molecular docking studies were performed against key breast cancer-related targets, including the estrogen receptor (2IOK), HER2 (7PCD), EGFR/SRC (1QCF) and HSP90 (8B7J). The docking results revealed strong binding interactions for all compounds, with compound 16 showing the highest docking affinity, while compound 15 demonstrated superior in-vitro cytotoxicity, highlighting the complementary nature of computational and biological evaluations. Furthermore, in silico ADME and toxicity analyses indicated favorable pharmacokinetic profiles, acceptable oral bioavailability and moderate predicted toxicity. All compounds satisfied Lipinski’s Rule of Five, falling within the optimal drug-like molecular weight range (200–500 g/mol), except compound 16. Overall, the combined experimental and computational results underscore the potential of oxazinyl–thiazolidinone scaffolds as promising lead candidates for the development of novel anti-breast cancer agents.
- 17 March 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 26 (02) , 1-23
Oxazinyl-Thiazolidinone Hybrids: Integrated Synthesis, Anticancer Activity, Molecular Docking and In-silico Pharmacokinetic Evaluation
A series of 3-(6-(furan-2-yl)-4-(4-nitrophenyl)-6H-1,3-oxazin-2-yl)-2-phenylthiazolidin-4-one derivatives (15–19) were synthesized via a silica-supported method and comprehensively characterized using FT-IR, 1 H and [ ]C NMR and mass spectrometry. The anticancer potential of these thiazolidinone–oxazine hybrids was evaluated against the MCF-7 breast cancer cell line using the MTT assay. All compounds displayed moderate cytotoxic activity, with IC[ ] values ranging from 51.20 to 87.10 [ ]M. Among them, the nitro-substituted compound 15 exhibited the highest cytotoxic potency (IC[ ] 51.20 [ ]M), which may be attributed to the electron-withdrawing effect of the nitro group. To rationalize the experimental findings, molecular docking studies were performed against key breast cancer-related targets, including the estrogen receptor (2IOK), HER2 (7PCD), EGFR/SRC (1QCF) and HSP90 (8B7J). The docking results revealed strong binding interactions for all compounds, with compound 16 showing the highest docking affinity, while compound 15 demonstrated superior in-vitro cytotoxicity, highlighting the complementary nature of computational and biological evaluations. Furthermore, in silico ADME and toxicity analyses indicated favorable pharmacokinetic profiles, acceptable oral bioavailability and moderate predicted toxicity. All compounds satisfied Lipinski’s Rule of Five, falling within the optimal drug-like molecular weight range (200–500 g/mol), except compound 16. Overall, the combined experimental and computational results underscore the potential of oxazinyl–thiazolidinone scaffolds as promising lead candidates for the development of novel anti-breast cancer agents.